Hiberix

Hiberix is a lyophilized powder for reconstitution that contains the Haemophilus influenzae type b (Hib) conjugate vaccine, using tetanus toxoid as a carrier protein. It is supplied in a single‑dose vial and is administered by intramuscular or subcutaneous injection. The product is authorized in the European Union and is prescribed for the active immunization of infants and young children against Hib disease through a standard immunization schedule.

Hiberix is indicated for the prevention of infections caused by Haemophilus influenzae type b in pediatric populations.

- Primary prevention of Hib meningitis, pneumonia, and epiglottitis in infants. - Use in routine childhood immunization programs according to national schedules. - Administration as part of a three‑dose primary series, typically at 2, 4, and 6 months of age. - Option to give a booster dose after the primary series, often at 12–15 months. - May be co‑administered with other pediatric vaccines such as DTaP, IPV, and PCV13.

Local and systemic reactions may occur after Hiberix injection; most are mild and resolve without intervention.

Common: - Pain, redness, or swelling at the injection site. - Low‑grade fever (≤38.5 °C) within 24–48 hours. - Irritability or fussiness in infants. - Mild fatigue or loss of appetite.

Serious: - High fever (≥39 °C) persisting more than 48 hours. - Severe allergic reaction (e.g., urticaria, angioedema, bronchospasm). - Seizures associated with fever. - Persistent crying or inconsolable distress lasting >3 hours.

Healthcare providers should assess each patient before administering Hiberix to ensure safe use and to identify conditions that may require special attention.

- Do not vaccinate children with a known severe allergy to any component of the vaccine, including tetanus toxoid. - Defer vaccination in individuals with a moderate or severe acute illness until recovery. - Observe the patient for at least 15 minutes after injection for immediate hypersensitivity reactions. - Use with caution in infants with a history of seizures or febrile convulsions. - Document previous Hib vaccination to avoid unnecessary repeat dosing. - Consider postponing the dose if the child is receiving immunosuppressive therapy.

Hiberix does not have many documented drug‑drug interactions, but certain clinical situations warrant attention.

Avoid: - Concurrent administration of live bacterial vaccines (e.g., oral typhoid) in the same limb, which may interfere with immune response. - Use in patients receiving high‑dose corticosteroids or other potent immunosuppressants without adjusting the schedule.

Use with caution: - Simultaneous receipt of multiple injectable vaccines; monitor for increased local reactogenicity. - Infants on antipyretic therapy may have attenuated fever response, potentially masking early signs of infection. - Patients with a history of Guillain‑Barré syndrome should be evaluated before vaccination.